Icatibant Acetate Drug Asset Due Diligence Report 2026

This Icatibant Acetate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Icatibant Acetate can convert its Small molecule drug profile and B2 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Icatibant Acetate (query alias: icatibant)
Modality / target	Small molecule drug; B2 receptor; B2 receptor antagonists
Highest global status	Approved
Originator	Shire Development LLC
Active developers	Accord Healthcare SL, Takeda Pharmaceuticals International AG, Shire Pharmaceuticals Services Ltd.

The MCP disease footprint includes Hereditary Angioedema, Hereditary Angioedema Types I and II. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20241595	Phase 4	已完成	115	Not disclosed
NCT07290855	Phase 4	Completed	5	To evaluate the time to complete or near complete resolution from onset of symptoms
NCT05834777	Phase 3	Recruiting	26	Blood pressure during hemodialysis

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

New Submission

Not Applicable; n=458; evaluation: Positive. Reported fields: Attack duration(when treated) = 24.0 hour ( 6 - 48)

Understanding The Reasons Not To Treat All HAE Attacks And Patient Satisfaction For On-Demand Treatment (ODT). Results From The HAE Wave II Disease Specific Program™ (DSP™) 2023

Not Applicable; n=258; evaluation: Negative. Reported fields: Adverse Event: Non-treated attacks with symptoms = Most experienced external swelling of the hands, arms, feet, legs, fingers or toes (59%), followed by abdominal pain (24%), and 13% resulted in the patient attending the ER ; Adverse Event: Non-treated attacks with symptoms = Most experienced external swelling of the hands, arms, feet, legs, fingers or toes (59%), followed by abdominal pain (24%), and 13% resulted in the patient attending the ER ; Adverse Event: Non-treated attacks with symptoms = Most experienced external swelling of the hands, arms, feet, legs, fingers or toes (59%), followed by abdominal pain (24%), and 13% resulted in the patient attending the ER

Three-day icatibant on top of standard care in patients with COVID-19 pneumonia (ICAT·COVID): a randomized, open-label, phase 2, proof-of-concept trial.

Phase 2; n=73; evaluation: Positive. Reported fields: Clinical Response = 55.6 % ; Clinical Response = 73.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Icatibant Acetate addresses Hereditary Angioedema, Hereditary Angioedema Types I and II. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-08-03	AbbVie, Amgen, and Takeda collaborate on the I-SPY clinical trial to investigate the efficacy of cenicriviroc, Otezla, and Firazyr in treating Covid-19.	Approved	Financial terms not disclosed
2020-01-28	Sandoz launches generic Icatibant in US for rare disease hereditary angioedema, strategically enhancing injectables portfolio	Approved	Financial terms not disclosed
2001-11-13	Aventis and Jerini sign Icatibant deal	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of icatibant and derivatives thereof in preparation of tumor diagnosis and/or treatment reagent”. The milestone feed surfaced a patent-application signal described as “Method for icatibant preparation”. The milestone feed surfaced a patent-application signal described as “Discovey of icatibant acetate for treating coronaviridae family of virus”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO